MB
PHAT icon

MPM BioImpact’s Phathom Pharmaceuticals PHAT Stock Holding History

MPM BioImpact’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-70,000
Closed -$639K – 41
2023
Q4 		$639K Sell
70,000
-277,332
-80% -$2.39M 0.15% 32
2023
Q3 		$3.6M Buy
347,332
+65,000
+23% +$892K 0.96% 29
2023
Q2 		$4.04M Buy
282,332
+69,717
+33% +$804K 0.81% 30
2023
Q1 		$1.52M Buy
212,615
+16,673
+9% +$146K 0.39% 27
2022
Q4 		$2.2M Buy
195,942
+2,616
+1% +$27K 0.57% 27
2022
Q3 		$2.14M Hold
193,326
– – 0.51% 30
2022
Q2 		$1.63M Hold
193,326
– – 0.45% 33
2022
Q1 		$2.63M Buy
+193,326
New +$3.12M 0.71% 32

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

MPM BioImpact's PHAT Position: Q1 2024 in Review

MPM BioImpact sold out of Phathom Pharmaceuticals (PHAT) in Q1 2024, closing a stake of 70,000 shares — an estimated $639K sold.

MPM BioImpact first reported a position in PHAT in Q1 2022 and held it in 8 quarters. The position peaked at $4.04M in Q2 2023. 114 funds tracked by Wall St. Rank hold PHAT as of Q1 2024.

  • MPM BioImpact reported no remaining Phathom Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • MPM BioImpact sold 70,000 Phathom Pharmaceuticals shares in Q1 2024, an estimated $639K.
  • MPM BioImpact first reported a position in Phathom Pharmaceuticals in Q1 2022 and held it in 8 quarters.
  • MPM BioImpact's Phathom Pharmaceuticals position peaked at $4.04M in Q2 2023.
  • 114 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2024.

Based on MPM BioImpact's 13F filing for Q1 2024, filed 15 May 2024.